• Something wrong with this record ?

Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism

A. Aido, O. Zaitseva, H. Wajant, M. Buzgo, A. Simaite

. 2021 ; 13 (7) : . [pub] 20210713

Language English Country Switzerland

Document type Journal Article

Grant support
813871 Horizon 2020

Conventional bivalent IgG antibodies targeting a subgroup of receptors of the TNF superfamily (TNFSF) including fibroblast growth factor-inducible 14 (anti-Fn14) typically display no or only very limited agonistic activity on their own and can only trigger receptor signaling by crosslinking or when bound to Fcγ receptors (FcγR). Both result in proximity of multiple antibody-bound TNFRSF receptor (TNFR) molecules, which enables engagement of TNFR-associated signaling pathways. Here, we have linked anti-Fn14 antibodies to gold nanoparticles to mimic the "activating" effect of plasma membrane-presented FcγR-anchored anti-Fn14 antibodies. We functionalized gold nanoparticles with poly-ethylene glycol (PEG) linkers and then coupled antibodies to the PEG surface of the nanoparticles. We found that Fn14 binding of the anti-Fn14 antibodies PDL192 and 5B6 is preserved upon attachment to the nanoparticles. More importantly, the gold nanoparticle-presented anti-Fn14 antibody molecules displayed strong agonistic activity. Our results suggest that conjugation of monoclonal anti-TNFR antibodies to gold nanoparticles can be exploited to uncover their latent agonism, e.g., for immunotherapeutic applications.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024391
003      
CZ-PrNML
005      
20211013133940.0
007      
ta
008      
211006s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics13071072 $2 doi
035    __
$a (PubMed)34371763
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Aido, Ahmed $u InoCure s.r.o, Department of R&D, Prumyslová 1960, 250 88 Celákovice, Czech Republic $u Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Auverahaus, Grombühlstrasse 12, 97080 Würzburg, Germany
245    10
$a Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism / $c A. Aido, O. Zaitseva, H. Wajant, M. Buzgo, A. Simaite
520    9_
$a Conventional bivalent IgG antibodies targeting a subgroup of receptors of the TNF superfamily (TNFSF) including fibroblast growth factor-inducible 14 (anti-Fn14) typically display no or only very limited agonistic activity on their own and can only trigger receptor signaling by crosslinking or when bound to Fcγ receptors (FcγR). Both result in proximity of multiple antibody-bound TNFRSF receptor (TNFR) molecules, which enables engagement of TNFR-associated signaling pathways. Here, we have linked anti-Fn14 antibodies to gold nanoparticles to mimic the "activating" effect of plasma membrane-presented FcγR-anchored anti-Fn14 antibodies. We functionalized gold nanoparticles with poly-ethylene glycol (PEG) linkers and then coupled antibodies to the PEG surface of the nanoparticles. We found that Fn14 binding of the anti-Fn14 antibodies PDL192 and 5B6 is preserved upon attachment to the nanoparticles. More importantly, the gold nanoparticle-presented anti-Fn14 antibody molecules displayed strong agonistic activity. Our results suggest that conjugation of monoclonal anti-TNFR antibodies to gold nanoparticles can be exploited to uncover their latent agonism, e.g., for immunotherapeutic applications.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zaitseva, Olena $u Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Auverahaus, Grombühlstrasse 12, 97080 Würzburg, Germany
700    1_
$a Wajant, Harald $u Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Auverahaus, Grombühlstrasse 12, 97080 Würzburg, Germany
700    1_
$a Buzgo, Matej $u InoCure s.r.o, Department of R&D, Prumyslová 1960, 250 88 Celákovice, Czech Republic
700    1_
$a Simaite, Aiva $u InoCure s.r.o, Department of R&D, Prumyslová 1960, 250 88 Celákovice, Czech Republic
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 13, č. 7 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34371763 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20211013133937 $b ABA008
999    __
$a ind $b bmc $g 1708303 $s 1144888
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 7 $e 20210713 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a 813871 $p Horizon 2020
LZP    __
$a Pubmed-20211006

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...